Combination of oral acitretin, antiretroviral therapy, human papillomavirus vaccine, and carbon dioxide laser ablation for the treatment of giant condyloma acuminatum of the vulva in a patient with AIDS

Namuduri, R.; Lee, Lynette Ying; Koh, Mark Jean‐Aan

doi:10.1111/dth.14253

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunosuppressed patients may experience therapeutic benefits from HPV vaccination, as demonstrated in a case report where complete clearance of recalcitrant warts occurred in a patient with idiopathic immune deficiency following qHPV vaccination, similar to one of the aforementioned studies [ 31 , 95 ]. Two of the selected studies also emphasized the efficacy of the HPV vaccine in severe manifestations of immunosuppression, such as giant condyloma acuminata and epidermodysplasia, resulting in complete remission of these otherwise challenging-to-manage cases [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Șandru,

Radu,

Petca

et al. 2024

Vaccines

View full text Add to dashboard Cite

Human papillomavirus (HPV) encompasses a diverse array of viruses, comprising approximately 200 serotypes that affect humans. While the majority of HPV strains are associated with benign skin or mucous membrane growths, a subset is implicated in severe health conditions, such as cervical, anal, vulvar, and vaginal cancers. Despite the established effectiveness of HPV vaccines in preventing cervical and anal carcinomas in particular, their therapeutic potential in addressing cutaneous diseases linked to diverse HPV strains remains an intriguing area of investigation. This narrative review critically examines the existing literature to assess the viability of HPV immunization as a therapeutic intervention for prevalent cutaneous conditions. These include genital and extragenital cutaneous warts, epidermodysplasia verruciformis, and keratinocyte carcinomas. The findings suggest a promising dual role for HPV vaccines in preventing and treating dermatologic conditions while emphasizing future research directions, including the immunization perspective against β-HPVs. Moreover, the presence of conflicting study outcomes underscores the imperative for larger-scale, randomized trials with well-matched control groups to validate the efficacy of HPV immunization in the dermatologic context. This review contributes valuable insights into the evolving landscape of HPV-vaccine applications in the field of dermatology.

show abstract